Ondansetron-13C-d3 (Synonyms: GR 38032-13C,d3; SN 307-13C,d3) |
| Catalog No.GC47827 |
A neuropeptide with diverse biological activities
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2699607-85-5
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Ondansetron-13C-d3 is intended for use as an internal standard for the quantification of ondansetron by GC- or LC-MS. Ondansetron is an antagonist of the serotonin (5-HT) receptor subtype 5-HT3 receptor (Ki = 1.6 nM).1 It is selective for the 5-HT3 receptor over the 5-HT1A-D, 5-HT2, and 5-HT4 receptors (Kis = >1,200 nM). It inhibits 5-HT-induced depolarization of isolated rat vagus nerve and contraction of isolated guinea pig ilium longitudinal muscle-myenteric plexus preparations in a concentration-dependent manner ex vivo.2 In a ferret model of cisplatin-induced emesis, ondansetron reduces the number of retching and vomiting episodes and increases the latency time to vomit when administered at a dose of 0.01 mg/kg and eliminates retching and vomiting when administered at a dose of 0.1 mg/kg.3 Ondansetron (0.5 and 1 mg/kg) also decreases immobility time in a forced swim test and increases time spent in the light chamber and latency to leave the light chamber in the light/dark exploration test in a mouse model of diabetes induced by streptozotocin , indicating antidepressant-like and anxiolytic activities.4 Formulations containing ondansetron have been used in the treatment of nausea and vomiting associated with chemotherapy, radiotherapy, or following surgery.
1.van Wijingaarden, I., Hamminga, D., van Hes, R., et al.Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annelated indole derivativesJournal of Medicinal Chemistry36(23)3693-3699(1993) 2.Butler, A., Hill, J.M., Ireland, S.J., et al.Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptorsBr. J. Pharmacol.94(2)397-412(1988) 3.Stables, R., Andrews, P.L.R., Bailey, H.E., et al.Antiemetic properties of the 5HT3-receptor antagonist, GR38032FCancer Treat. Rev.14(3-4)333-336(1987) 4.Gupta, D., Radhakrishnan, M., and Kurhe, Y.Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: Possible implication of serotonergic systemEur. J. Pharmacol.74459-66(2014)
| Cas No. | 2699607-85-5 | SDF | |
| Synonyms | GR 38032-13C,d3; SN 307-13C,d3 | ||
| Canonical SMILES | O=C1C(CN2C(C)=NC=C2)CCC3=C1C(C=CC=C4)=C4N3[13C]([2H])([2H])[2H] | ||
| Formula | C17[13C]H16D3N3O | M.Wt | 297.4 |
| Solubility | DMSO: 0.1 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3625 mL | 16.8124 mL | 33.6247 mL |
| 5 mM | 0.6725 mL | 3.3625 mL | 6.7249 mL |
| 10 mM | 0.3362 mL | 1.6812 mL | 3.3625 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *